4.6 Article

Cancer-associated fibroblasts: Secretions, interactions, and therapy

期刊

JOURNAL OF CELLULAR BIOCHEMISTRY
卷 120, 期 3, 页码 2791-2800

出版社

WILEY
DOI: 10.1002/jcb.27703

关键词

cancer; cancer-associated fibroblasts; extracellular matrix; therapy; transforming growth factor-beta; tumor microenvironment

向作者/读者索取更多资源

Tumor microenvironment (TME) could impose a great challenge for cancer targeted therapies. Immunosuppression within the TME creates a barrier between cancer cells and therapeutic approaches. A number of cells are hosted within this milieu, among them cancer-associated fibroblasts (CAFs) are the most abundant cell populations playing major roles in mediating an immunosuppressive TME. CAFs have cross-talks with almost all cells within the TME for reprogramming them into being tumorigenic. This reprogramming reduces the pre-existing tumor immunity and dampens the efficacy of chemotherapeutic approaches. CAFs would do this through releasing a myriad of factors to the TME making it an appropriate nest for tumor growth. The cells degrade and deposit extracellular matrix components, both of which are tumorigenic. Therefore, disruption of cross-talks between CAFs with other cells within the TME would be a promising approach in cancer targeted therapies. This approach is applicable through dampening dominant signals mediated by CAFs. Another interesting approach would be reprogramming of CAFs toward their normal counterpart. This would need identification of different subtypes for these cells and their functions. More knowledge is also required about selective markers for each CAF subtype.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

The interactions of paclitaxel with tumour microenvironment

Ding-Li Yu, Zhi-Ping Lou, Feng-Yun Ma, Masoud Najafi

Summary: Interactions within the tumour microenvironment (TME) play a crucial role in cancer therapy. Paclitaxel, a commonly used chemotherapy drug, not only inhibits cell cycle but also modulates interactions in TME to suppress tumour growth. This review discusses the effects of paclitaxel on anti-tumour immunity, immunosuppressive cells, hypoxia, and angiogenesis, and suggests targeting these interactions to improve therapy efficiency.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Imperatorin Attenuates the Proliferation of MCF-7 Cells in Combination with Radiotherapy or Hyperthermia

Peyman Amini, Saeedeh Jafari Nodooshan, Milad Ashrafizadeh, Akbar Aliasgharzadeh, Zarichehr Vakili, Saeed Tavakoli, Tayebeh Aryafar, Ahmed Eleojo Musa, Masoud Najafi, Shahram Taeb, Bagher Farhood

Summary: In this study, imperatorin (IMP) was found to enhance the effectiveness of external radiotherapy (ERT) and hyperthermia (HT) in breast cancer cells by increasing the expression of pro-apoptotic genes and reducing the levels of the anti-apoptotic protein Bcl-2, leading to a decrease in cell viability.

CURRENT RADIOPHARMACEUTICALS (2022)

Review Immunology

Dysregulated metabolism: A friend-to-foe skewer of macrophages

Keywan Mortezaee, Jamal Majidpoor

Summary: Tumor-associated macrophages (TAMs) are immune cells that infiltrate tumor areas and have intense interactions with other cells. The metabolic abnormalities in tumors can affect the polarization of macrophages towards pro-tumor or anti-tumor phenotypes. Adjusting the metabolic systems of macrophages can be an effective tool in cancer therapy.

INTERNATIONAL REVIEWS OF IMMUNOLOGY (2023)

Review Cell Biology

Mechanisms of cancer cell killing by metformin: a review on different cell death pathways

Xiao-yu Wu, Wen-Wen Xu, Xiang-kun Huan, Guan-nan Wu, Gang Li, Yu-Hong Zhou, Masoud Najafi

Summary: Resistance of cancer cells to anti-tumour agents is a major challenge in cancer treatment. Metformin, an antidiabetic drug, can enhance cell death mechanisms and play a key role in inducing cell death, thereby increasing the therapeutic efficiency of anti-cancer therapy.

MOLECULAR AND CELLULAR BIOCHEMISTRY (2023)

Review Pharmacology & Pharmacy

Apigenin in cancer therapy: Prevention of genomic instability and anticancer mechanisms

Masoud Moslehi, Sepideh Rezaei, Pourya Talebzadeh, Mohammad Javed Ansari, Mohammed Abed Jawad, Abduladheem Turki Jalil, Nima Rastegar-Pouyani, Emad Jafarzadeh, Shahram Taeb, Masoud Najafi

Summary: The incidence of cancer is increasing globally. The long-term adverse effects of cancer therapy and tumor resistance to anticancer agents are major concerns. Apigenin, a plant-derived molecule, has potential as an adjuvant for chemoprevention and overcoming malignancy resistance to cancer therapy. It has promising anti-tumor effects and may reduce genomic instability and risks of second malignancies in normal tissues, as well as improve the efficacy of anticancer modalities.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2023)

Review Cell Biology

Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated

Keywan Mortezaee, Jamal Majidpoor

Summary: The low frequency of durable responses in patients treated with immune checkpoint inhibitors (ICIs) requires additional strategies to enhance immune responses against cancer. Transforming growth factor-beta (TGF-beta) is a cytokine often expressed in tumors and promotes an immunosuppressive tumor microenvironment (TME). TGF-beta also influences the efficacy of anti-PD-1/PD-L1 therapy. Combining TGF-beta inhibitors with anti-PD(L)1 has shown promising results, and clinical trials are currently underway to investigate the use of agents with bifunctional capacity and fusion proteins to reinvigorate immune responses against advanced stage cancers, particularly those with an immunologically cold ecosystem.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2023)

Review Immunology

Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated

Arian Charehjoo, Jamal Majidpoor, Keywan Mortezaee

Summary: Metabolic alterations occur commonly in tumor cells to adapt energetic sources for proliferation, survival, and resistance. IDO1 is an enzyme that degrades tryptophan and its upregulation in cancer stroma impacts immune tolerance and cancer evasion. IDO1 inhibitors combined with immune checkpoint inhibitors show promise in treating advanced solid tumors and overcoming ICI therapy bypass.

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

Review Immunology

B7x in cancer immunity and immunotherapy

Keywan Mortezaee

Summary: B7x is a co-inhibitory molecule highly expressed in non-inflamed cancers, contributing to cancer progression and poor outcomes. It hampers peripheral immune responses and promotes immunosuppressive cells and regulatory T cells in cancer. Evaluation of B7x in sera is a potential biomarker for cancer patient response. B7x overexpression is involved in tumor resistance to immune checkpoint inhibitor therapy, but anti-B7x treatment can reinvigorate exhausted T cells and complement conventional ICI therapy. The development of bispecific antibodies against B7x and other regulatory molecules is an advance in the field.

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

Review Instruments & Instrumentation

Extracellular vesicle-based drug delivery in cancer immunotherapy

Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee

Summary: Extracellular vesicles (EVs) are membrane-bound organelles released from eukaryotic cells that can be used as biomarkers for human diseases. EVs have favorable features as ideal drug carriers and vaccines for diseases including cancer.

DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2023)

Review Multidisciplinary Sciences

Anti-PD-(L)1 therapy of non-small cell lung cancer-A summary of clinical trials and current progresses

Keywan Mortezaee, Jamal Majidpoor

Summary: This review discusses the impact of mono or combination therapy of immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC) patients, comparing clinical outcomes and safety. Cancer subtype, tumor mutational burden (TMB), programmed death-ligand 1 (PD-L1) expression state and T cell infiltration (TIL) density are considered for interpretations. Besides, current progresses in the field of immunotherapy are discussed.

HELIYON (2023)

Article Medicine, Research & Experimental

Advances in dendritic cell vaccination therapy of cancer

Sajad Najafi, Keywan Mortezaee

Summary: Traditionally, vaccines have played a crucial role in eradicating infectious diseases and saving millions of lives. However, the development of anticancer vaccines faces challenges and requires further optimization. Dendritic cells, as the most potent antigen presenting cells, have been used in tumor immunotherapies but their efficacy needs improvement.

BIOMEDICINE & PHARMACOTHERAPY (2023)

Review Pathology

The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4

Sasan Parvini, Jamal Majidpoor, Keywan Mortezaee

Summary: This review focuses on the impact of PD-L1 on combo nivolumab-ipilimumab therapy in advanced solid cancer patients, indicating that patient responses can be affected by different levels of PD-L1 expression. Variations in responses are observed among different cancer types or doses of immunotherapy drugs. Therefore, relying solely on PD-L1 as a biomarker may not be reliable for predicting the clinical efficacy of combo nivolumab-ipilimumab. Other biomarkers or a combination of PD-L1 with other factors should be considered for predicting patient responses.

PATHOLOGY RESEARCH AND PRACTICE (2023)

Review Oncology

The impact of hypoxia on extracellular vesicle secretome profile of cancer

Keywan Mortezaee, Jamal Majidpoor

Summary: Extracellular vesicles (EVs), particularly exosomes, play a crucial role in the communication and signal transmission between tumor cells and the tumor microenvironment (TME). Hypoxia, a characteristic of TME, stimulates tumor cells to release more EVs, which transfer biological information to promote hypoxia and hypoxia inducible factor (HIF) functionality. The EVs secreted under hypoxic conditions carry pro-tumorigenic factors that contribute to various tumor-related processes including cancer cell proliferation and survival, immune escape, angiogenesis, invasion, metastasis, and therapy resistance. This review focuses on the interplay between hypoxia and EVs, particularly exosomes, and their impact on key hallmarks of cancer.

MEDICAL ONCOLOGY (2023)

Review Oncology

NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives

Keywan Mortezaee, Jamal Majidpoor

Summary: NK cells, as lymphoid cells of innate immunity, play important roles in immune surveillance and immunotherapy. However, the decreased cytotoxic activity and reduced number of activating receptors limit their application in cellular immunotherapy.

MEDICAL ONCOLOGY (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Evaluation of set-up errors and estimation of set-up margin during external beam radiation therapy of prostate cancer using electronic portal imaging device (EPID)

Daryoush Khoramian, Soroush Sistani, Bagher Farhood

Summary: The study measured systematic and random set-up errors in prostate cancer radiotherapy using EPID and proposed the optimum CTV-to-PTV margin. Results showed population systematic and random errors in different directions, leading to calculated margins based on different formulas, with overall margins averaging at 2.73, 4.98 and 5.86 mm.

JOURNAL OF RADIOTHERAPY IN PRACTICE (2022)

暂无数据